EF24 |
Catalog No.GC64496
One-Click Copy Product Info
|
EF24 es un nuevo análogo sintético de la curcumina
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 342808-40-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
EF24 es un nuevo análogo sintético de la curcumina [1]. EF24 induce la apoptosis de células cancerosas a través de un mecanismo dependiente de redox [2]. EF24 tiene efectos antitumorales y antienvejecimiento [3-4].
En células A549, EF24 (0μM, 0.5μM, 1μM, 2μM, 4μM, 8μM, 16μM; 24h, 48h) inhibe el crecimiento de células de NSCLC in vitro [5]. En las células K562, EF24 (2μM; 24h) exhibe una potente actividad de muerte celulr en líneas celulares de leucemia [6]. En SKOV-3, el tratamiento EF24 (3μM; 48h) atenúa la proliferación y metástasis de células de cáncer de ovario[7].
En el modelo de ratones tumorales HCC subcutáneos, EF24 (20mg/kg; ip; 21d) inhibe el crecimiento tumoral e induce la apoptosis [8]. En ratpnes C57/BL6, EF24 (200μg/kg; ip; 14d) inhibió significativamente el aumento significativo en los niveles de JunB, JunC y JunD en tejidos pulmonares distantes después de la irradiación infrarroja[9]. En el modelo de ratones tumorales subcutáneos DU145, el tratamiento EF24 (200μg/kg; ip; 4 semanas) redujo significativamente el crecimiento tumoral [10].
References:
[1]. He Y, Li W, Hu G, et al. Bioactivities of EF24, a novel curcumin analog: a review. Frontiers in Oncology. 2018 Dec 11; 8: 614.
[2]. Adams BK, Cai J, Armstrong J, et al. EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. Anti-cancer drugs. 2005 Mar 1;16(3):263-275.
[3]. Sazdova I, Keremidarska-Markova M, Dimitrova D, et al. Anticarcinogenic potency of EF24: An overview of its pharmacokinetics, efficacy, mechanism of action, and nanoformulation for drug delivery. Cancers. 2023 Nov 20; 15(22): 5478.
[4]. Li W, He Y, Zhang R, et al. The curcumin analog EF24 is a novel senolytic agent. Aging (Albany NY). 2019 Jan 28;11(2):771.
[5]. Chang M, Shang M, Yuan F, et al. EF24 exerts cytotoxicity against NSCLC via inducing ROS accumulation. Cancer Cell International. 2021 Dec; 21: 1-3.
[6]. Singh AP, Wax N, Duncan J, et al. Genomic Discovery of EF-24 Targets Unveils Antitumorigenic Mechanisms in Leukemia Cells. bioRxiv. 2024 Oct 16: 2024-2010.
[7]. Zhang D, Wang Y, Dong L, et al. Therapeutic role of EF 24 targeting glucose transporter 1‐mediated metabolism and metastasis in ovarian cancer cells. Cancer science. 2013 Dec; 104(12): 1690-1696.
[8]. Liu H, Liang Y, Wang L, et al. In vivo and in vitro suppression of hepatocellular carcinoma by EF24, a curcumin analog. PloS one. 2012 Oct 31; 7(10): e48075.
[9]. Veeraraghavan J, Natarajan M, Awasthi V, et al. EF24, a novel curcumin analogue inhibits oncogenic activation induced by radiation abscopal effect in distant mice lungs. Cancer Research. 2011 Apr 15;71(8_Supplement):4203.
[10]. Yang CH, Yue J, Sims M, et al. The curcumin analog EF24 targets NF-κB and miRNA-21, and has potent anticancer activity in vitro and in vivo. PloS one. 2013 Aug 7; 8(8): e71130.
| Experimentos celulares [1]: | |
Líneas celulares | Células A549 |
Método de preparación | Para los ensayos de crecimiento/viabilidad celular (MTT), las células A549 se sembraron en placas estándar de 96 pozos con 4000 células y se les permitió crecer durante 24 horas para garantizar la unión. El medio de crecimiento fue luego reemplazado por un medio que contenía EF24 a la concentración final de 0 μM, 0,5 μM, 1 μM, 2 μM, 4 μM, 8 μM y 16 μM. |
Condiciones de reacción | 0 μM, 0,5 μM, 1 μM, 2 μM, 4 μM, 8 μM, 16 μM; 24h, 48h |
Áreas de aplicación | EF24 inhibe el crecimiento de células de NSCLC in vitro. |
| Experimentos con animales [2]: | |
Modelos animales | Modelo de ratón tumor subcutáneo del CHC |
Método de preparación | Aproximadamente 2×106 células Hepa1-6 en 200µL de PBS se inyectaron por vía subcutánea en la espalda de cada animal (n = 20). EF24 se disolvió en dimetil sulfóxido y se diluyó en cloruro de sodio. Diez días después de la inyección, los ratones tratados con EF24 (n = 10) fueron inyectados por vía intraperitoneal (i.p.) con 200 µL de EF24 a una dosis de 20 mg/kg/d durante 21 días. A los ratones de control (n = 10) se les inyectó i.p. con 200µL de PBS al día. El día 22, los tumores fueron extirpados y pesados. |
Forma de dosificación | 20 mg/kg; ip; 21d |
Áreas de aplicación | EF24 inhibe el crecimiento tumoral e induce la apoptosis en un modelo de tumor subcutáneo del CHC. |
References: | |
| Cas No. | 342808-40-6 | SDF | |
| Formula | C19H15F2NO | M.Wt | 311.33 |
| Solubility | Storage | Store at -20°C | |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.212 mL | 16.0601 mL | 32.1203 mL |
| 5 mM | 642.4 μL | 3.212 mL | 6.4241 mL |
| 10 mM | 321.2 μL | 1.606 mL | 3.212 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)